Qiagen N.V. (QGEN)

Market Cap	8.66B -2.3%
Revenue (ttm)	2.09B +5.7%
Net Income	424.88M +408.3%
EPS	2.04 +409.8%
Shares Out	216.92M
PE Ratio	19.55
Forward PE	15.91
Dividend	$2.41 (6.04%)
Ex-Dividend Date	Jan 8, 2026

Volume	2,137,145
Open	40.29
Previous Close	40.65
Day's Range	39.78 - 40.43
52-Week Range	39.78 - 57.82
Beta	0.71
Analysts	Buy
Price Target	51.30 (+28.48%)
Earnings Date	May 6, 2026

About QGEN

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 28, 1996
• Employees: 5,967
• Stock Exchange: NYSE
• Ticker Symbol: QGEN
• Website: https://www.qiagen.com

Financial Performance

In 2025, Qiagen's revenue was $2.09 billion, an increase of 5.65% compared to the previous year's $1.98 billion. Earnings were $424.88 million, an increase of 408.28%.

Analyst Summary

According to 9 analysts, the average rating for QGEN stock is "Buy." The 12-month stock price target is $51.3, which is an increase of 28.48% from the latest price.

Price Target

$51.3

(28.48% upside)

Analyst Consensus: Buy